Allogene Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 233
- Market Cap
- $560.4M
- Website
- http://www.allogene.com
- Introduction
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge
Gene therapy clinical trials gain momentum with over 180 companies advancing treatments, leveraging technologies like CRISPR/Cas9 for precision. Key therapies include ZOLGENSMA for spinal muscular atrophy and LUXTURNA for inherited retinal diseases. Challenges include immune reactions, long-term effects, and high costs, necessitating ethical oversight and equitable access.
Allogene Therapeutics (ALLO) Stock Surges Amid Biotechnology Sector Volatility
Allogene Therapeutics stock rose 5.02% to $2.83, with zero revenue, a $66.36M net loss, and -$0.35 EPS. Despite financial losses, 72% of 18 institutions recommend buying. The biotech sector declined 0.19%, but stocks like Bright Minds Biosciences and Psyence Biomedical gained. Allogene specializes in immuno-oncology, developing allogeneic T-cell products for cancer and autoimmune diseases.
Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma
Real-world outcomes of relapsed/refractory multiple myeloma patients treated with cilta-cel showed 89% overall response rate and 70% complete response, despite many being ineligible for the trial leading to its approval. Median 12-month progression-free survival was 68% and overall survival 82%, with similar serious side effects reported.
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Allogene Therapeutics to participate in Goldman Sachs Cell Therapy Day panel on Oct 1, 2024, discussing allogeneic cell therapy innovations. Webcast available on Allogene's website.
Renal Cancer Clinical Trial Pipeline Appears Robust With
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene
Gene editing therapeutics market estimated at $11 million in 2024, forecasted to grow at 147% CAGR to reach $1 billion by 2029, driven by chronic diseases, rare disorders, strategic initiatives, and precision medicine.
$600M+ Credit Firm Targets Life-Sci Companies in Later Stages
Arie Belldegrun, MD, launches Symbiotic Capital, a global life sciences credit firm with over $600 million in capital, to fund startups needing cash amidst sluggish equity markets. Symbiotic extends non-dilutive senior secure term loans, focusing on stability and maturity of companies, with investments ranging from $20 million to $200 million. The firm is disease agnostic and diversifies across life sciences sectors, aiming to align with companies' success through equity conversion and warrant positions.
© Copyright 2025. All Rights Reserved by MedPath